Full-Time

Art Supervisor

Updated on 9/3/2026

EVERSANA

EVERSANA

1,001-5,000 employees

Commercial services for pharmaceutical lifecycle management

Compensation Overview

$90.6k - $131k/yr

Chicago, IL, USA

Remote

Category
Art, Graphics & Animation (1)
Required Skills
Adobe InDesign
UI/UX Design
Figma

Get referred to EVERSANA

See people who can refer or advise you

Requirements
  • 6+ years of experience
  • The ability to lead and elevate art/design across the team, adding value wherever possible
  • Adept at providing constructive feedback to more junior-level creatives, advancing the creative from both a copy and art standpoint
  • Possesses strong conceptual skills with the ability to bring a wide range of creative solutions to every project
  • Leads art direction across projects ranging in scope, complexity, and channel to create a cohesive brand experience that meets/exceeds expectations
  • Proficiency in Figma and Adobe InDesign is required, with the ability to confidently execute design work across digital and print formats
  • Proficient in estimating individual hours (for oneself and direct reports) for a variety of different projects
  • Ability to use advanced design principals to distill complex scientific information and turn it into compelling, clear data visualizations for our brands
  • Mastery of file-building/management best practices and The One Intouch Process
  • Understands the importance of utilization and works hard to hit targets for themselves and direct reports
  • Knowledge of accessibility best practices and a commitment to apply them to our work
  • Mentors and grows junior team members, elevating their designs and expanding their industry knowledge
  • Growing knowledge of our clients’ business and how our work impacts the business
  • Proactively works in close concert with planning, UX, and development to ensure team alignment
  • Develops strong relationships with creative, account management, product management, production, studio, and cross functional team members
  • Confidently presents and helps sell ideas to our clients
  • Volunteers to contribute to new business efforts
  • Mastery in developing multichannel creative (within portfolio) that displays strong conceptual thinking, strategic/business acumen, and finely crafted designs
  • A wide range of industry experience including launches, label updates, etc.
  • Interest and experience in leveraging emerging AI tools to support and elevate creative work
  • Demonstrate a commitment to diversity, equity, and inclusion through continuous development, modeling inclusive behaviors, and proactively managing bias.
Desired Qualifications
  • Interest and experience in leveraging emerging AI tools to support and elevate creative work
  • Demonstrate a commitment to diversity, equity, and inclusion through continuous development, modeling inclusive behaviors, and proactively managing bias.
  • Volunteers to contribute to new business efforts

EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Milwaukee, Wisconsin

Founded

2018

Get referred to EVERSANA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lundbeck expanded its EVERSANA AI Agency partnership on August 25, 2026, validating the platform.
  • Candel Therapeutics and Xcovery both tapped EVERSANA for U.S. launches in 2026.
  • The August 20, 2026 platform expansion opens medical information, market access, and patient-services workflows.

What critics are saying

  • Revelio Labs showed EVERSANA headcount slipped 1.3% to 3,634 by March 2026.
  • Jussen v. EVERSANA and Leichtman v. EVERSANA expose employment and discrimination litigation costs.
  • If Waltz Health integration stalls, the $6 billion platform thesis unravels against PBM incumbents.

What makes EVERSANA unique

  • EVERSANA merged with Waltz Health on August 26, 2025, uniting commercialization and drug-access software.
  • Its AI Agency platform, launched in 2025, now spans medical affairs, market research, and MLR automation.
  • EVERSANA serves 650-plus organizations, giving it reach across biotech launches and established pharmaceutical brands.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 25th, 2026
Lundbeck and EVERSANA announce strategic partnership to advance ai-powered commercialization.

Lundbeck and EVERSANA announce strategic partnership to advance ai-powered commercialization. Aug 25, 2026, 07:59 ET Collaboration expands deployment of EVERSANA's AI Agency platform and commercialization capabilities to advance Lundbeck's Focused Innovator strategy and bionic ambitions CHICAGO and DEERFIELD, Ill., Aug. 25, 2026 /PRNewswire/ - Lundbeck, a global pharmaceutical company focused exclusively on brain health, and EVERSANA(R), a leading global provider of commercial services to the life sciences industry, today announced a strategic partnership to advance AI-powered commercialization across Lundbeck's U.S. commercial organization. The collaboration will broaden Lundbeck's use of EVERSANA's AI Agency platform and related commercialization capabilities, creating a scalable framework for accelerating strategy development, content creation, omnichannel engagement and commercial execution. The partnership supports Lundbeck's Focused Innovator strategy and ambition to build bionic capabilities, bringing human expertise and artificial intelligence together to achieve results neither can deliver alone. The companies share a commitment to deploying AI responsibly and at scale while maintaining the compliance, quality, scientific rigor and governance standards required for the life sciences industry to best serve healthcare providers, patients, families and communities. "At Lundbeck, building bionic capabilities is an important part of how we are advancing our Focused Innovator strategy," said Tom Gibbs, EVP and President, Lundbeck U.S. "Our ambition is to bring human expertise and artificial intelligence together to strengthen how we think, decide and execute across our business. Building on the progress we have made with EVERSANA, our expanded collaboration will help us scale bionic capabilities responsibly across our commercial organization, improve the speed and quality of execution and ultimately, help us deliver greater value to our customers and patients while maintaining the high standards that define our business." The announcement follows the successful deployment of EVERSANA's AI-powered capabilities in support of Lundbeck's commercialization activities. Through the initial work, Lundbeck and EVERSANA introduced AI-driven workflows to accelerate strategic planning, content development and commercial execution while maintaining rigorous medical, legal and regulatory review processes. Through the expanded partnership, Lundbeck will scale AI-enabled commercialization capabilities across multiple areas, including marketing, medical communications, market access and media operations. The companies will also explore additional use cases designed to enhance operational performance and commercial excellence. "The future of commercialization will belong to organizations that successfully combine human expertise with AI-driven execution," said Mark Thierer, Chief Executive Officer, EVERSANA. "Lundbeck is advancing innovation and actively implementing new ways of working. Together, we are creating a model that pairs the power of artificial intelligence with deep life sciences expertise to help commercial teams move faster, operate more efficiently and deliver greater impact." Launched in 2025, EVERSANA's AI Agency is an end-to-end AI-powered commercialization platform built specifically for life sciences. Developed in collaboration with Google Cloud, the platform combines agentic AI, advanced automation and human expertise to accelerate the development of strategy, content and omnichannel engagement while supporting compliance and governance requirements unique to the pharmaceutical industry. "What makes this partnership unique is that we're not simply introducing AI tools into existing workflows," said Faruk Capan, Chief Innovation Officer, EVERSANA. "Together, we're implementing an AI-powered operating model designed specifically for life sciences. By combining agentic AI, embedded compliance and human expertise, we can help commercial teams accelerate execution while maintaining the quality and scientific rigor the industry demands." The strategic partnership supports Lundbeck's Focused Innovator strategy and bionic ambitions. By combining AI-powered capabilities with deep industry expertise, Lundbeck is helping shape how the next generation of pharmaceutical commercialization will be designed and delivered. About Lundbeck Lundbeck is a global biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long-term value for our shareholders by making positive contributions to patients, their families and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. Lundbeck US comprises the wholly owned US subsidiaries of H. Lundbeck A/S (HLUNa / HLUNb, HLUNA DC / HLUNB DC) ("Lundbeck"), including Lundbeck LLC and Lundbeck Pharmaceuticals LLC. For additional information, please visit Lundbeck.com/us and connect with us on LinkedIn, Instagram, and X at @LundbeckUS. About EVERSANA(R) EVERSANA(R) is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA(R), visit eversana.com or connect through LinkedIn and X. Media Contact EVERSANA Matt Braun Vice President, Corporate Communications [email protected] SOURCE EVERSANA

PR Newswire
Aug 20th, 2026
EVERSANA expands AI-powered platform across medical affairs and commercial operations

EVERSANA has expanded its AI-powered commercialisation platform beyond marketing to include medical affairs, market research, and field sales team engagement. The platform, which combines agentic AI orchestration, workflow automation, and enterprise data capabilities, now offers solutions for medical information, market research, MLR automation, and analytics. The company is developing additional features for market access, patient services, and sales enablement. The platform aims to help life sciences organisations improve efficiency whilst maintaining industry compliance and governance requirements. "Organizations are moving beyond isolated AI pilots and looking for practical ways to scale AI across commercialisation," said Mark Thierer, EVERSANA's chief executive officer. The company serves more than 650 organisations globally. EVERSANA will showcase the platform at an event on 27 August in New York.

PR Newswire
Jun 9th, 2026
EVERSANA appoints Jen Norton as President of Market Access & Value to lead integrated business unit

EVERSANA, a global provider of commercial services to the life sciences industry, has appointed Jen Norton as President, Market Access & Value. Norton will lead a new dedicated market access business unit integrating EVERSANA's services across global pricing, revenue management, value and evidence, and consulting. Norton brings over 20 years of market access leadership experience. She joins from Takeda, where she served as Senior Vice President and Head of U.S. Patient and Market Access, and previously held senior positions at Amgen and Biogen. The new unit reinforces EVERSANA's commitment to helping clients navigate the complex pricing and access landscape. CEO Mark Thierer said successfully navigating market access is amongst the most critical challenges clients face today. EVERSANA serves over 650 organisations in the life sciences industry.

PR Newswire
May 6th, 2026
EVERSANA appoints Mike Guarino as CEO of global health agency EVERSANA INTOUCH

EVERSANA has appointed Mike Guarino as chief executive officer of EVERSANA INTOUCH, its global health agency. Guarino will lead strategy and operations across the agency's capabilities, focusing on integrating commercialisation opportunities through data and AI to deliver marketing solutions for life sciences clients. Guarino brings extensive agency experience, most recently serving as chief commercial officer at IPG Health. He spent over two decades in senior roles at FCB Health and co-founded Area 23. Senior leaders including Ann Cave, Susan Perlbachs, John Kenny and Dan Gandor will report to Guarino. Founder Faruk Capan will shift focus to expanding the company's AI Agency platform, launched in collaboration with Google in August 2025. EVERSANA provides commercial services to the life sciences industry, serving over 650 organisations globally.

PharmaLIVE
Apr 29th, 2026
Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy.

Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy. Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement with EVERSANA, a provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer. Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access, and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel's virtual Research and Development Day in December 2025. This collaboration reflects Candel's deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer, subject to regulatory approval. This operating model gives Candel access to leading commercial capabilities while maintaining financial flexibility, capital efficiency, and scientific focus that has driven Candel's progress to date. "From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "With the addition of EVERSANA, that model is fully in place, and with the progress we've already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer. We look forward to working with EVERSANA and IDEA Pharma in providing a novel and potentially invaluable therapeutic for localized prostate cancer patients." "We are proud to support Candel as it advances what could be a new and potentially transformative treatment option for patients with localized prostate cancer," said Gregory Skalicky, President of EVERSANA. "Candel's unique approach to commercialization, building a dedicated and flexible platform with specialized partners, rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support. We have already integrated our resources alongside the Candel team, with key commercial workstreams actively underway, and we look forward to helping ensure that aglatimagene reaches patients efficiently and effectively upon potential approval."